#USA #Scottsdale #CND Life Sciences #Neurodiagnostics #Innovation Laboratory

CND Life Sciences Unveils Its New Innovation Laboratory

On September 17, 2026, CND Life Sciences, Inc., a leading entity in the field of medical technology, marked a significant milestone with the inauguration of its new Innovation Laboratory in Scottsdale, Arizona. The event was celebrated with a festive ribbon-cutting ceremony that brought together employees, community members, and stakeholders. This new facility is poised to enhance CND’s capabilities in advancing neurodiagnostic tests and develop innovative biomarker solutions aimed at improving patient care.

The Innovation Laboratory represents a critical enhancement to CND's existing infrastructure, supporting the company's vision for growth and innovation. It provides specialized space dedicated to assay development, biomarker research, technology evaluation, and translational research, effectively complementing the clinical operations of CND, which are certified by CLIA and CAP.

Dr. Todd Levine, CND’s Chief Medical Officer and Co-Founder, expressed enthusiasm about the laboratory's opening, highlighting that it demonstrates CND's commitment to investing in scientific capabilities. This new facility is intended to serve clinicians and researchers better, signifying a step forward in CND's long-term vision.

Located conveniently near CND's headquarters, the Innovation Laboratory fosters collaboration among scientific, product development, and operational teams. It is designed to facilitate access to the resources and talent required to drive CND's next growth phase. According to Dr. Christopher Gibbons, Chief Scientific Officer and Co-Founder, the laboratory reinforces CND's mission by providing an environment conducive to exploring groundbreaking scientific opportunities and developing therapies for neurodegenerative diseases.

CND Life Sciences has a history of innovation in neurodiagnostics, particularly with its flagship product, the Syn-One Test®, a laboratory-developed test (LDT) designed to assist clinicians in diagnosing patients suspected of having synucleinopathies. The Syn-One Test utilizes advanced techniques to detect phosphorylated alpha-synuclein in cutaneous nerves and measures other signs of peripheral nerve degeneration, showcasing CND's focus on precision medicine.

In a pivotal study published in the Journal of the American Medical Association (JAMA) in 2024, the Syn-One Test demonstrated the ability to identify phosphorylated alpha-synuclein in 95.5% of participants who were clinically diagnosed with a synucleinopathy. This compelling data underscores the utility of the Syn-One Test in clinical evaluations and has attracted the attention of over 3,500 clinicians utilizing the test for more than 70,000 patients.

The establishment of the Innovation Laboratory not only indicates CND's commitment to improving diagnostic capabilities but also illustrates its dedication to contributing to Arizona's burgeoning biotechnology and medical technology landscape. As the lab prepares to begin operations shortly, there is a palpable sense of optimism about the potential scientific advancements that lie ahead.

As CND Life Sciences moves forward with its innovative pursuits, it remains focused on building strong collaborations with biopharmaceutical companies for clinical trials and investigations on early disease detection and biomarker quantification. The future looks bright for CND as they continue to forge paths toward better patient diagnostics and therapeutic solutions in the realm of neurodegenerative diseases.

For additional insights into CND Life Sciences and its innovative offerings, visit cndlifesciences.com or connect with them on LinkedIn. The opening of this new laboratory reinforces the company's determination to lead in its field and provide critical solutions for patients facing the challenges of neurodegenerative conditions.